Alnylam Pharmaceuticals Inc (ALNY)vsIncyte Corporation (INCY)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
INCY
Incyte Corporation
$92.23
+1.78%
HEALTHCARE · Cap: $18.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 38% more annual revenue ($5.14B vs $3.71B). INCY leads profitability with a 25.0% profit margin vs 8.5%. INCY trades at a lower P/E of 14.1x. INCY earns a higher WallStSmart Score of 83/100 (A-).
ALNY
Hold49
out of 100
Grade: D+
INCY
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+67.0%
Fair Value
$299.99
Current Price
$92.23
$207.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 25.6%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.0% and operating margin at 25.6%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while INCY is a growth play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.84 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
INCY generates stronger free cash flow (521M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 49/100), backed by strong 25.0% margins and 27.8% revenue growth. Both earn "Exceptional Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?